- Home
- CQP vs ONC Comparison
CQP vs ONC Comparison
Compare CQP & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CQP
- ONC
- Stock Information
- Founded
- CQP 2003
- ONC 2010
- Country
- CQP United States
- ONC Switzerland
- Employees
- CQP N/A
- ONC N/A
- Industry
- CQP Oil/Gas Transmission
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- CQP Utilities
- ONC Health Care
- Exchange
- CQP Nasdaq
- ONC Nasdaq
- Market Cap
- CQP 28.4B
- ONC 26.9B
- IPO Year
- CQP 2007
- ONC N/A
- Fundamental
- Price
- CQP $55.70
- ONC $243.64
- Analyst Decision
- CQP Strong Sell
- ONC Strong Buy
- Analyst Count
- CQP 5
- ONC 9
- Target Price
- CQP $55.80
- ONC $325.56
- AVG Volume (30 Days)
- CQP 228.2K
- ONC 346.9K
- Earning Date
- CQP 08-07-2025
- ONC 08-06-2025
- Dividend Yield
- CQP 5.88%
- ONC N/A
- EPS Growth
- CQP N/A
- ONC N/A
- EPS
- CQP 4.16
- ONC N/A
- Revenue
- CQP $9,398,000,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- CQP $27.02
- ONC $869.15
- Revenue Next Year
- CQP N/A
- ONC $19.07
- P/E Ratio
- CQP $13.41
- ONC N/A
- Revenue Growth
- CQP 3.94
- ONC 51.16
- 52 Week Low
- CQP $47.00
- ONC $142.00
- 52 Week High
- CQP $68.42
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- CQP 41.74
- ONC N/A
- Support Level
- CQP $54.60
- ONC N/A
- Resistance Level
- CQP $56.70
- ONC N/A
- Average True Range (ATR)
- CQP 1.58
- ONC 0.00
- MACD
- CQP -0.10
- ONC 0.00
- Stochastic Oscillator
- CQP 20.11
- ONC 0.00
About CQP Cheniere Energy Partners LP Common Units
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The revenue generated through those activities is split with parent and operator Cheniere Energy.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.